Globalstar, Inc (NASDAQ:GSAT) saw its shares soar this morning up over 30% heading into midday trading, with a rise of over $.30 to $1.35 and nearly four times its daily volume traded. This rise is due in large part to the FCC News Globalstar, Inc received today.

The Federal Communications Commission (FCC) announced that Globalstar, Inc. will be allowed to operate its second-generation satellites within the boundaries of the United States.  This authority will become effective once Globalstar Inc, completes registration of the new satellites in France.

Globalstar, Inc. has already launched six satellites for the second generation constellation and recently received six new satellites for an upcoming May launch date. After the May launch, Globalstar, Inc. is expecting two more launches each containing six satellites. These additional satellites within the current Constellation will provide improved coverage throughout the United States for Globalstar, Inc. customers.

About Globalstar, Inc.
Globalstar, Inc. provides mobile voice and data communications services through satellite in the United States and Canada. It provides duplex services comprising mobile voice and data satellite communications, satellite data modem, and fixed voice and data satellite communications services; and simplex services, including personal, asset tracking, and remote monitoring.

Celera Corporation (NASDAQ:CRA) saw shares soar this morning up over 29% rising $1.86 with a whopping 26 million shares traded heading into midday trading hours. This is a monumental increase from their daily average trading volume of 400,000 shares.

Quest Diagnostics Inc. ( NYSE:DGX) a Madison, New Jersey based medical laboratory operator announced that it would purchase all of Celera Corps outstanding shares for $8 per share. The $671 million deal price also includes Celera’s cash and short term investments. The $8 purchase price is a 28% premium from where shares of Celera Corp closed on Thursday March 17, 2011.

With this acquisition Quest Diagnostics Inc. gains it access to proprietary genetic testing and a research and development pipeline focusing on cardiovascular disease and cancer. The acquisition also come on the heels of Celera Corp’s announcement of a Q4 net income drop of 31%. As product licensing and revenue declined the companies earnings did as well falling to $2.5 million down from the $3.6 in Q4 of 2009.

About Celera Corporation
Celera Corporation, an Alameda, California based company, offers personalized disease management through a combination of products and services primarily in the United States.

Lucas Energy, Inc. (AMEX:LEI) saw shares rise this morning up over $.50 at one point. This morning’s share increase of over 15% comes on the news that LEI has acquired an interest in the ARCO Fee A-908 No.1 well. The well is back in production after being shutdown during LEI’s acquisition of it.

In a partial month of production in January the well produced 5,791 thousand cubic feet of natural gas and 371 barrels of condensate. This marks a new venture for the Houston based independent oil and gas company. William A. Sawyer, President and CEO of Lucas Energy, Inc, stated “Lucas energy is expanding its area of interest to include other leases along the same trend it is currently developing, this is Lucas Energy’s first gas well.”

Lucas Energy, Inc has another well located in the same area of the Austin Chalk Formation.  This second well has yet to be evaluated however Lucas Energy Inc does have a 50% working interest after payout in the two wells.

About Lucas Energy, Inc.

The company acquires low producing or abandoned oil wells with underlying potential. Lucas Energy currently has acreage in the fast growing Eagle Ford Trend in Central Texas. Lucas Energy’s business plan is to acquire wells at low cost, improve the production in the wells, and develop upside potential with joint venture partners.

New home construction saw a 22.5 percent decline in February from January. This decline came as a surprise to investors following a surge in apartment construction in January. This is just the latest evidence that the housing industry is still many years away from recovery. Only 479,000 were being built in February compared to the 600,000 in January according to the Commerce Department. This is the lowest level since April 2009 and the second-lowest in over a 50 years.

The main area of home construction, which is single-family homes, were down 11.8 percent in February. Construction of apartments and condominiums dropped 47%, taking out much of the gains in January. Building permits also fell 8.1 percent last month to the lowest levels since 1960.

Here’s a breakdown of the drop in home construction across the country.

Midwest – 48.6%
Northeast – 37.5%
West – 28%
South- 6.3%

The National Association of Home Builders said Tuesday that they have rated March a 17 on its index of industry sentiment. This is up from 16, where it has been for the past 5 months, but isn’t really good news though since any reading below 50 indicates negative sentiment about the housing industry’s future. The last time the index was above 50 was April 2006.

Impax Laboratories Inc (NASDAQ:IPXL) are showing a surge of over 10%  today rising over $2.80 to nearly $25 per share on over 3.5 million share traded by the midday trading hour. This is 5 times the average daily volume for IPXL shares.

This surge come on the news that Impax Laboratories Inc. proposed Parkinson’s drug (Candidate IPX066) met key treatment goals when compared to carbipoda-levopoda. IPX066 is an extended release version of its counterpart the immediate release carbipoda-levopoda. The IPX066 study focused on patients with varying degrees of fluctuations in motor function.

Impax Laboratories Inc. is also expected to discuss Advance-PD Phase-III study for in the treatment of Advanced Parkinson’s Disease. A Conference call was scheduled for this morning Tuesday March, 15 2011 at 9:00 AM Eastern to discuss these future studies.

About Impax Laboratories Inc.
The company operates in two divisions Global Pharmaceuticals and Impax Pharmaceuticals.  The Global Pharmaceuticals division develops, manufactures, and sells, and distributes generic pharmaceutical products to a variety of retail drug chains. The Imapx Pharmaceuticals division develops drugs that address the central nervous system.